Kidney Transplantation – An Urgent Need to Improve the Outcomes for Patients


Waiting lists for kidney transplants are getting longer, often 4-5 years or more.


The global need for organ transplants is projected to more than double in the next decade.


Too many patients on dialysis die each year waiting for a kidney transplant.

Transplanted Kidneys Often Fail Too Soon and the Cycle Begins Again


The average kidney transplant recipient experiences kidney failure within 10-12 years post-transplant and the cycle begins again.

The cycle of end-stage renal disease (ESRD), kidney failure, dialysis, kidney transplant, and back to kidney failure is a complex journey that many people living with kidney disease face. Too many kidney transplant recipients go through it more than once during their lifetime, transitioning between dialysis and transplantation multiple times depending on their health status, availability of donor organs, and other factors.

This cycle puts a tremendous burden on kidney transplant recipients, the healthcare system, providers, and payers. It may also be emotionally, physically, and financially taxing for transplant recipients and their families.

Eledon is striving to both extend the functional life of transplanted organs and reduce side effects of current immunosuppressive treatments such as kidney toxicity, high blood pressure, and tremor.

There has been little innovation for transplantation immunosuppressant therapies in almost 30 years. We’re working to change that. At Eledon, our mission is

One Transplant for Life.

We are advancing tegoprubart, a novel therapeutic in clinical development for patients receiving organ transplants.

Eledon is committed to improving the lives of patients by developing first-in-class/best-in-class treatments for transplantation and neurodegeneration. If you are a patient or healthcare professional interested in learning more about our current and planned clinical trials, please contact:

Patient Resources